Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.7%

9 terminated/withdrawn out of 77 trials

Success Rate

83.6%

-2.9% vs industry average

Late-Stage Pipeline

10%

8 trials in Phase 3/4

Results Transparency

2%

1 of 46 completed trials have results

Key Signals

10 recruiting1 with results4 withdrawn

Enrollment Performance

Analytics

N/A
39(60.9%)
Phase 2
10(15.6%)
Phase 1
6(9.4%)
Phase 4
5(7.8%)
Phase 3
3(4.7%)
Early Phase 1
1(1.6%)
64Total
N/A(39)
Phase 2(10)
Phase 1(6)
Phase 4(5)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (77)

Showing 20 of 77 trials
NCT07544498Not ApplicableNot Yet Recruiting

PIONEERING XR TECHNOLOGY FOR THE PROMOTION OF RESILIENCE AND MENTAL HEALTH OF THE HEALTHCARE WORKFORCE

Role: collaborator

NCT06456983Not ApplicableRecruiting

Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial

Role: lead

NCT06626789Phase 1Recruiting

Brain Signal Training to Enhance Affect Down-regulation

Role: lead

NCT02926859Phase 2Active Not Recruiting

Enhancing Recovery in Early Schizophrenia

Role: lead

NCT06845124Phase 2Recruiting

A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence

Role: lead

NCT06959342Not ApplicableRecruiting

Modification of Inhibitory Control and Craving Through Transcranial Direct Current Stimulation (tDCS) as an Add-On Treatment for Substance Use Disorder

Role: lead

NCT06346353Completed

Substance Consumption, Personality, and Cognitive Functioning of Chess Players

Role: lead

NCT03816527Withdrawn

Selective Attention in Alcohol Use Disorder

Role: lead

NCT05698615Not ApplicableCompleted

Chess Training as add-on Intervention for Adolescents With Psychiatric and Psychosomatic Disorders

Role: lead

NCT03765476Not ApplicableActive Not Recruiting

Validation of a Training Program for Patients With Alcohol Use Disorder

Role: lead

NCT06105853Not ApplicableRecruiting

Neurobehavioral Profiles of Adaptive Stress Responses in Individuals With Alcohol Use Disorder

Role: lead

NCT03911726Not ApplicableActive Not Recruiting

Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia

Role: lead

NCT02438202Not ApplicableNot Yet Recruiting

Electroconvulsive Therapy for Treatment of Alzheimer´s Disease

Role: lead

NCT06881810Phase 2Recruiting

Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment

Role: lead

NCT00916201Phase 1Withdrawn

Evaluation Study of New Compounds With Potential Use in Schizophrenia

Role: lead

NCT02492074Phase 1Withdrawn

Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study

Role: lead

NCT05726045Not ApplicableRecruiting

Increasing Smoking Cessation Success Through Sleep-amplified Memory Consolidation

Role: lead

NCT06247306Not ApplicableRecruiting

Using Neurofeedback to Understand the Relationship Between Stress and Alcohol Consumption

Role: lead

NCT04670081Phase 2Completed

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

Role: lead

NCT02088060Phase 2Terminated

A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients

Role: lead